XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened

Shares of XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.57 and traded as high as $2.74. XTL Biopharmaceuticals shares last traded at $2.70, with a volume of 45,674 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

XTL Biopharmaceuticals Trading Up 8.4%

The stock has a market capitalization of $5.94 million, a price-to-earnings ratio of -4.22 and a beta of 1.45. The business has a 50 day simple moving average of $2.57 and a 200-day simple moving average of $3.35.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.